Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis

Hepatology Communications 2026 Open access

Read full text
Authors: Zobair M Younossi, Fatema Nader, Dominic Labriola, Rebecca Taub, Andrei Racila, Linda Henry, Maria Stepanova
DOI: 10.1097/hc9.0000000000000913
Cited by: 5
References: 22

Abstract

BACKGROUND: Resmetirom is approved for MASH F2-F3 fibrosis. Health-related quality of life (HRQL) was assessed in patients with MASH treated with resmetirom. METHODS: Patients with MASH enrolled in MAESTRO-NAFLD-1 (NCT04197479) and the 52-week open-label extension study (year 2). HRQL was assessed using LDQoL and CLDQ-NAFLD. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) response definition for early MASH: a decrease ≥30% from baseline; MASH cirrhosis ≥20% decrease (if baseline MRI-PDFF >5%). RESULTS: MAESTRO-NAFLD-1 included 180 patients with MASH cirrhosis and 1143 with early MASH [baseline MRI-PDFF ≥8%, vibration-controlled transient elastography (VCTE) ≥5.5 kPa

Fields of Study & Subjects

Liver Disease and Transplantation Peripheral Neuropathies and Disorders Silymarin and Mushroom Poisoning

Publication details

Journal / source
Hepatology Communications
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
10
Issue
3
Publication date
26 February 2026
Language
EN